Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer

JAMA Neurology

Volumn 73, Issue 8, 2016, Pages 928-933

  Williams, Tanya J ^a   Benavides, David R ^a   Patrice, Kelly Ann ^a   Dalmau, Josep O ^b   De Ávila, Alexandre Leon Ribeiro ^c   Le, Dung T ^a   Lipson, Evan J ^a   Probasco, John C ^a   Mowry, Ellen M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DABRAFENIB; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 2; IPILIMUMAB; IRINOTECAN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NIVOLUMAB; PACLITAXEL; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; TRAMETINIB; VELIPARIB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ADULT; ALLERGIC ENCEPHALITIS; ARTICLE; BRAIN METASTASIS; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; MELANOMA; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; AGED; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; ENCEPHALITIS; HASHIMOTO DISEASE; SECONDARY;

AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; ENCEPHALITIS; FEMALE; HASHIMOTO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84981271733     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.1399     Document Type: Article

References (28)

1. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175.
2. Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 2015;4(5):661-672.
3. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42 (4):587-600.
4. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278-280.
5. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012; 30(6):e76-e78.
6. Bompaire F, Mateus C, Taillia H, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs. 2012;30(6): 2407-2410.
7. Boyd K, Kalladka D, Overell J, Waterston A. Ipilimumab induced encephalitis: a case report. Immunome Res. 2015;11:092. doi:10.4172/1745-7580.1000092
8. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16(4):589-593.
9. Conry RM, Sullivan JC, Nabors LB III. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3 (6):598-601.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
11. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543-1554.
12. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1): 63-74.
13. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
14. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17): 5866-5875.
15. Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015; 138(pt 1):94-109.
16. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8): 828-833.
17. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21(3):173-187.
18. Valpione S, Zoccarato M, Parrozzani R, et al. Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. J Neurol Sci. 2013;335(1-2): 210-212.
19. Hauspy J, Nevin A, Harley I, et al. Paraneoplastic syndrome in vaginal melanoma: a case report and review of the literature. Int J Gynecol Cancer. 2007;17(5):1159-1163.
20. Wei X, Walia V, Lin JC, et al; NISC Comparative Sequencing Program. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43(5):442-446.
21. Yang XZ, Cui LY, Ren HT, Qu T, Guan HZ. Anti-NMDAR encephalitis after resection of melanocytic nevi: report of two cases. BMC Neurol. 2015;15:165.
22. Prickett TD, Zerlanko BJ, Hill VK, et al. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. J Invest Dermatol. 2014;134(9):2390-2398.
23. Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology. 2013; 81(18):1637-1639.
24. Venkatesan A, Benavides DR. Autoimmune encephalitis and its relation to infection. Curr Neurol Neurosci Rep. 2015;15(3):3.
25. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
26. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118(6):737-743.
27. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27 (26):4260-4267.
28. Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165(1-2): 166-171.